PAR Formulations Private Limited Lansoprazole Export Data — India (DGFT 2022–2026)

Name: PAR Formulations Private Limited Lansoprazole Export Records India — #3 Exporter, 95 Shipments, $4.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Lansoprazole

India Pharmaceutical Trade Intelligence

$290.2M316 Suppliers105 CountriesHS 30049034

ExportsIndia → CANADA54.9%India → UNITED STATES20.7%

ImportsISRAEL → India$8.3M UNITED STATES → India$178.0K

#1 Supplier: SANDOZ PRIVATE #1 Buyer: SANDOZ CANADA

PAR Formulations Private Limited — Lansoprazole Exporter #3 | $4.8M Trade Value | TransData Nexus | TransData Nexus

PAR Formulations Private Limited — Lansoprazole Exporter Profile

Indian Pharmaceutical Exporter · #3 for Lansoprazole · $4.8M export value · DGFT Verified

PAR Formulations Private Limited is the #3 Indian exporter of Lansoprazole with $4.8M in export value and 95 verified shipments. PAR Formulations Private Limited holds a 1.6% market share in Lansoprazole exports across 1 countries. The company exports 11 pharmaceutical products worth $35.0M across 8 therapeutic categories.

PAR Formulations Private Limited — Lansoprazole Export Profile: Buyers & Destinations

PAR Formulations Private Limited Lansoprazole export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Lansoprazole?

Country	Value	Shipments	Share
UNITED STATES	$30.5M	610	39.6%
FRANCE	$9.1M	246	11.8%
SOUTH AFRICA	$5.8M	142	7.6%
GUATEMALA	$5.0M	99

Who Are the Top Buyers of Lansoprazole from India?

Buyer	Country	Value	Orders
MYLAN IRELAND C/O ALLOGA RDC,	NETHERLANDS	$3.2M	81
NUEVOS ETICOS NEOETHICALS, S.A.	GUATEMALA	$2.8M	55
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$1.9M	39
SANDOZ CANADA INC.	CANADA	$1.8M	36
MYLAN PHARMACEUTICALS INC,	UNITED STATES	$1.7M	34
CSP VIATRIS SANTE AT CSP- LAB,	FRANCE	$1.4M	28
CAPITAL PHARMACY	OMAN	$1.2M	24
RISING PHARMA HOLDINGS INC	UNITED STATES	$750.0K	15
HEKO PHARMACY LTD	TANZANIA	$700.0K	14
SANDOZ CANADA INC	CANADA	$650.0K	13

India's Lansoprazole is purchased by 687 buyers worldwide. The top buyer is MYLAN IRELAND C/O ALLOGA RDC, (NETHERLANDS), followed by NUEVOS ETICOS NEOETHICALS, S.A. and EVERSANA LIFE SCIENCE SERVICES.

How Does PAR Formulations Private Limited Compare to Nearest Lansoprazole Exporters?

Exporters ranked immediately above and below #3 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
6	CAPLIN POINT LABORATORIES LIMITED	$6.4M	128	7	$50.0K
8	DR.REDDY'S LABORATORIES LTD	$5.2M	109	3	$47.6K
3	PAR FORMULATIONS PRIVATE LIMITED ★	$4.8M	95	1	$50.0K
9	HETERO LABS LIMITED	$4.6M	154	10	$30.1K
10	MICRO LABS LIMITED	$3.7M	87	16	$42.7K

PAR Formulations Private Limited ranks #3 among 316 Indian Lansoprazole exporters. Average shipment value of $50.0K compared to the market average of $227.0K. The closest competitors by value are CAPLIN POINT LABORATORIES LIMITED and DR.REDDY'S LABORATORIES LTD.

Which Indian Ports Ship Lansoprazole Exports?

Port	Shipments	% Share
SAHAR AIR	729	15.0%
DELHI AIR CARGO ACC (INDEL4)	577	11.9%
SAHAR AIR CARGO ACC (INBOM4)	416	8.5%
DELHI AIR	364	7.5%
NHAVA SHEVA SEA (INNSA1)	264	5.4%
JNPT/ NHAVA SHEVA SEA	209	4.3%
Bombay Air	140	2.9%
JNPT	106	2.2%

Geopolitical & Trade Policy Impact on PAR Formulations Private Limited's Lansoprazole Exports

The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like PAR Formulations. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight costs and extended transit times. These logistical challenges can impact the timely delivery of pharmaceutical products, potentially affecting supply chain reliability and customer satisfaction. According to Pharmaceutical Commerce, such disruptions could jeopardize up to $600 million in Indian pharmaceutical exports to the region.

Conversely, the ongoing US-China trade tensions have created openings for Indian pharmaceutical companies to capture a larger share of the US market. With the US imposing tariffs on Chinese goods, Indian exporters have the opportunity to position themselves as reliable alternative suppliers. However, this advantage is tempered by the US's own tariff policies, which have introduced uncertainties for Indian exporters. As reported by AP News, the US has imposed broad tariffs on imports from over 60 countries, including India, with rates reaching as high as 39%. These tariffs could impact nearly 55% of India's outbound shipments to America, posing a significant challenge for exporters like PAR Formulations.

In the European Union, regulatory changes such as the Falsified Medicines Directive (FMD) have imposed stringent compliance requirements on pharmaceutical imports. Indian exporters must adapt to these regulations to maintain access to the EU market. The India–EFTA Trade and Economic Partnership Agreement, effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially benefiting exporters like PAR Formulations. However, compliance with EU regulations remains a critical factor for market access.

PAR Formulations Private Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing intensified regulatory scrutiny, particularly from agencies like the US FDA and the European Medicines Agency. For Indian exporters, adherence to Good Manufacturing Practices (GMP) and other quality standards is imperative to ensure market access and maintain credibility. Instances of non-compliance can lead to import alerts, product recalls, and reputational damage. According to Fact Net, the US FDA conducted more than 200 inspections in India in 2023, with plans to increase this number in 2024, highlighting the critical importance of compliance for exporters like PAR Formulations.

PAR Formulations' commitment to quality and compliance is essential in this context. By investing in robust quality management systems and staying abreast of evolving regulatory requirements, the company can mitigate risks associated with non-compliance. This proactive approach not only ensures uninterrupted market access but also enhances the company's reputation as a reliable supplier in the global pharmaceutical landscape.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Lansoprazole shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: PAR Formulations Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 105+ countries, 687+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Lansoprazole

Lansoprazole

PAR Formulations Private Limited — Lansoprazole Exporter Profile

PAR Formulations Private Limited — Lansoprazole Export Profile: Buyers & Destinations

Where Does India Export Lansoprazole?

Who Are the Top Buyers of Lansoprazole from India?

What Is India's Total Lansoprazole Export Value and How Much Does PAR Formulations Private Limited Contribute?

What Is the Average Shipment Value for PAR Formulations Private Limited's Lansoprazole Exports?

How Does PAR Formulations Private Limited Compare to Other Indian Lansoprazole Exporters?

Regulatory Requirements: Exporting Lansoprazole to Key Markets

United States — FDA

South Africa — SAHPRA

How Does PAR Formulations Private Limited Compare to Nearest Lansoprazole Exporters?

Which Indian Ports Ship Lansoprazole Exports?

Geopolitical & Trade Policy Impact on PAR Formulations Private Limited's Lansoprazole Exports

PAR Formulations Private Limited — Regulatory Compliance & Quality Standards

About PAR Formulations Private Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Lansoprazole Export Data from PAR Formulations Private Limited

Lansoprazole Stats

Company Overview

Top Products by PAR Formulations Private Limited

Related Analysis

Need Detailed Export Data?

Data Source